Inspire Medical Systems (NYSE:INSP) Updates FY 2026 Earnings Guidance

Inspire Medical Systems (NYSE:INSP) issued an update on its FY 2026 earnings guidance on Monday morning. The company provided earnings per share guidance of 0.750-1.250 for the period, compared to the consensus earnings per share estimate of 1.990. The company issued revenue guidance of $825.0 million-$875.0 million, compared to the consensus revenue estimate of $961.2 million.

Analyst Ratings Changes

A number of equities analysts have commented on the company. UBS Group set a $67.00 target price on Inspire Medical Systems in a report on Friday, February 13th. Royal Bank Of Canada reissued a “sector perform” rating and set a $56.00 target price on shares of Inspire Medical Systems in a report on Tuesday, April 14th. Evercore reissued an “outperform” rating on shares of Inspire Medical Systems in a report on Friday, February 27th. Piper Sandler reduced their target price on Inspire Medical Systems from $165.00 to $85.00 and set an “overweight” rating for the company in a report on Thursday, February 12th. Finally, Stifel Nicolaus reduced their target price on Inspire Medical Systems from $85.00 to $70.00 and set a “buy” rating for the company in a report on Friday, April 10th. Five analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Inspire Medical Systems currently has a consensus rating of “Hold” and a consensus price target of $101.41.

Inspire Medical Systems Stock Performance

Shares of INSP stock traded down $1.93 during trading hours on Monday, reaching $54.77. The company had a trading volume of 1,586,372 shares, compared to its average volume of 1,178,608. The stock has a fifty day moving average of $56.73 and a 200-day moving average of $79.64. The company has a market capitalization of $1.58 billion, a price-to-earnings ratio of 11.00, a PEG ratio of 2.92 and a beta of 0.83. Inspire Medical Systems has a 12-month low of $48.30 and a 12-month high of $163.35.

Inspire Medical Systems (NYSE:INSP) last posted its quarterly earnings results on Monday, May 4th. The company reported $0.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.38. The business had revenue of $204.58 million during the quarter, compared to analyst estimates of $200.04 million. Inspire Medical Systems had a return on equity of 10.96% and a net margin of 15.95%.Inspire Medical Systems has set its FY 2026 guidance at 0.750-1.250 EPS. On average, analysts forecast that Inspire Medical Systems will post 1.82 EPS for the current year.

Institutional Investors Weigh In On Inspire Medical Systems

Large investors have recently made changes to their positions in the stock. Smartleaf Asset Management LLC grew its position in shares of Inspire Medical Systems by 84.0% in the fourth quarter. Smartleaf Asset Management LLC now owns 449 shares of the company’s stock valued at $42,000 after purchasing an additional 205 shares in the last quarter. Larson Financial Group LLC grew its position in Inspire Medical Systems by 21,266.7% in the third quarter. Larson Financial Group LLC now owns 641 shares of the company’s stock worth $48,000 after acquiring an additional 638 shares during the period. Quarry LP grew its position in Inspire Medical Systems by 695.1% in the fourth quarter. Quarry LP now owns 644 shares of the company’s stock worth $59,000 after acquiring an additional 563 shares during the period. Daiwa Securities Group Inc. grew its position in Inspire Medical Systems by 38.7% in the second quarter. Daiwa Securities Group Inc. now owns 466 shares of the company’s stock worth $60,000 after acquiring an additional 130 shares during the period. Finally, Parallel Advisors LLC grew its position in Inspire Medical Systems by 349.7% in the fourth quarter. Parallel Advisors LLC now owns 715 shares of the company’s stock worth $66,000 after acquiring an additional 556 shares during the period. 94.91% of the stock is currently owned by hedge funds and other institutional investors.

About Inspire Medical Systems

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.